Poster-Disease-modifying Therapy
October 25, 2021
Agnos Study Design: A Phase 4 Study Assessing Ofatumumab in Treatment-Naïve Young Adults with Early Relapsing Remitting MS Benchmarked Against Healthy Controls
Background: Early intervention with high efficacy therapies has been shown to reduce long-term disability accrual in patients with multiple...
Poster-Disease-modifying Therapy
October 25, 2021
Safety and Efficacy of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis Identifying As Hispanic from the Expand Study
Background: In the Phase 3 EXPAND trial siponimod, a selective S1P receptor modulator, significantly reduced risk of 3-month and 6-month...